A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer

Annals of Thoracic Surgery

Volumn 98, Issue 4, 2014, Pages 1152-1159

  Port, Jeffrey L ^a   Parashar, Bhupesh ^a   Osakwe, Nonso ^a   Nasar, Abu ^a   Lee, Paul C ^a   Paul, Subroto ^a   Stiles, Brendon M ^a   Altorki, Nasser K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CESIUM 131; IODINE 125; RADIOACTIVE SEED;

AGED; BRACHYTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DOSIMETRY; FATIGUE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HEART ATRIUM FIBRILLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LENGTH OF STAY; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; MORTALITY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT PREFERENCE; PNEUMONIA; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; STEREOTACTIC BODY RADIATION THERAPY; THORAX PAIN; VIDEO ASSISTED THORACOSCOPIC SURGERY; WEDGE RESECTION; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY;

AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY;

EID: 84908103333     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2014.04.128     Document Type: Conference Paper

References (20)

1. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
2. C.J. Haasbeek, D. Palma, O. Visser, F.J. Lagerwaard, B. Slotman, and S. Senan Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands Ann Oncol 23 2012 2743 2747
3. F.J. Lagerwaard, C.J. Haasbeek, E.F. Smit, B.J. Slotman, and S. Senan Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 70 2008 685 692
4. Y. Nagata, K. Takayama, and Y. Matsuo Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame Int J Radiat Oncol Biol Phys 63 2005 1427 1431
5. H. Onishi, H. Shirato, and Y. Nagata Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2 7 Suppl 3 2007 S94 S100
6. T. Xia, H. Li, and Q. Sun Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer Int J Radiat Oncol Biol Phys 66 2006 117 125
7. H.C. Fernando, and R. Timmerman American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer J Thorac Cardiovasc Surg 144 2012 S35 S38
8. I.S. Grills, V.S. Mangona, and R. Welsh Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer J Clin Oncol 28 2010 928 935
9. F.J. Lagerwaard, N.E. Verstegen, and C.J. Haasbeek Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer Int J Radiat Oncol Biol Phys 83 2012 348 353
10. A.V. Louie, G. Rodrigues, and M. Hannouf Stereotactic body radiotherapy versus surgery for medically operable stage I non-small-cell lung cancer: a Markov model-based decision analysis Int J Radiat Oncol Biol Phys 81 2011 964 973
11. S. Mahmood, H. Bilal, C. Faivre-Finn, and R. Shah Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I non-small-cell lung cancer? Interact Cardiovasc Thorac Surg 17 2013 845 853
12. J. Varlotto, A. Fakiris, and J. Flickinger Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery Cancer 119 2013 2683 2691
13. N.E. Verstegen, J.W. Oosterhuis, and D.A. Palma Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis Ann Oncol 24 2013 1543 1548
14. M.S. Allen, G.E. Darling, T.T. Pechet ACOSOG Z0030 Study Group Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial Ann Thorac Surg 81 2006 1013 1020
15. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf.
16. G.S. Sibley Radiotherapy for patients with medically inoperable Stage I nonsmall cell lung carcinoma: smaller volumes and higher doses - a review Cancer 82 1998 433 438
17. F.B. Zimmermann, H. Geinitz, and S. Schill Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer Lung Cancer 48 2005 107 114
18. A.J. Fakiris, R.C. McGarry, and C.T. Yiannoutsos Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study Int J Radiat Oncol Biol Phys 75 2009 677 682
19. Y. Nagata, K. Takayama, and Y. Matsuo Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame Int J Radiat Oncol Biol Phys 63 2005 1427 1431
20. H.C. Fernando, J.R. Landrenaeu, and S.J. Mandrekar Impact of brachytherapy on local recurrence after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer [Abstract] J Clin Oncol 31 Suppl 2013 abstr 7502